相关实验视频
Updated: Jan 17, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
杜皮卢马布在患有球状皮虫症和同时出现的亚托皮症的患者中
Katerina Jobst1, Stephan R Künzel2,3, Stefan Beissert1
1Department of Dermatology, Faculty of Medicine Carl Gustav Carus, University Allergy Center, Technische Universität Dresden, Dresden, Germany.
Frontiers in pharmacology
|September 15, 2025
概括
杜皮卢马布在一小群患者中有效治疗了球状皮炎 (BP) 和亚托皮炎 (AD). 所有患者在12周内实现了皮肤病变的缓解和明显减少,显示出高满意度和耐受性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 球状皮炎 (BP) 和亚托皮炎 (AD) 是慢性炎症性皮肤疾病.
- 这两种疾病都有相似的免疫反应,特别是2型免疫.
- 杜皮卢马布是一种IL-4Rα抗剂,在治疗高血压和AD方面表现有前途.
研究的目的:
- 评估dupilumab在患有血压和AD的患者中的疗效和安全性.
- 评估dupilumab对皮肤病变,和患者满意度的影响.
主要方法:
- 十二名中度至重度高血压患者的回顾性病例系列,以及阿尔茨海默病史.
- 患者接受dupilumab治疗时间为12周.
- 使用BPDAI得分,性NRS和DLQI来测量临床结果.
主要成果:
- 百分之百的患者在第12周内完全缓解了状病变,83.3%的患者在第4周内完全缓解了病变.
- 观察到明显的改善 (p < 0.0001),58.3%的人在第12周经历了完全的缓解.
- 杜皮卢马布耐受性良好,没有报告的不良事件,患者报告满意度高 (5/5).
结论:
- 杜皮卢马布是同时患有血压和AD的患者的安全有效治疗方法.
- 它提供快速和持续的症状控制,解决皮肤病变,并导致高患者满意度.
- 药物耐受性很好,即使在患有多种并发病症的老年患者中也是如此.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493

